Templates by BIGtheme NET
Stethoscope

HC Stocks Newsbeat! GlaxoSmithKline plc (GSK), ACADIA Pharmaceuticals Inc. (ACAD)

Shares of GlaxoSmithKline plc (ADR) (NYSE:GSK) ended Wednesday session in green amid volatile trading. The shares closed up +1.26 points or 3.22% at $40.40 with 7.36 million shares getting traded. Post opening the session at $40.18, the shares hit an intraday low of $39.60 and an intraday high of $40.60 and the price vacillated in this range throughout the day. The company has a market cap of $97.89 billion and the numbers of outstanding shares have been calculated to be 4.88 billion shares.

GlaxoSmithKline plc (ADR) (GSK) discovers, develops, manufactures, and markets pharmaceutical products, counting vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company operates through five segments: Global Pharmaceuticals, HIV, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It offers pharmaceutical products in the therapeutic areas, counting respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ended Wednesday session in green amid volatile trading. The shares closed up +2.03 points or 7.56% at $28.87 with 5.74 million shares getting traded. Post opening the session at $28.09, the shares hit an intraday low of $27.37 and an intraday high of $29.20 and the price vacillated in this range throughout the day. The company has a market cap of $4.08 billion and the numbers of outstanding shares have been calculated to be 121.11 million shares.

ACADIA Pharmaceuticals Inc. (ACAD) recently declared its unaudited financial results for the third quarter ended September 30, 2016.

Financial Results

Revenue

ACADIA stated net product sales of $5.3 million for the three months ended September 30, 2016. No similar net product sales were stated for the comparable period of 2015. NUPLAZID was made available for prescription starting May 31, 2016. Through ACADIA’s NUPLAZIDconnect™ site, upon initiation of therapy, physicians are able to prescribe patients a 30-day free trial of NUPLAZID for which no revenue is recognized.

Research and Development

Research and development expenses raised to $25.8 million for the three months ended September 30, 2016 from $18.7 million for the comparable period of 2015. This increase was mainly because of raised clinical costs related to the development of pimavanserin in indications other than Parkinson’s disease psychosis and a boost in personnel and related costs associated with ACADIA’s expanded research and development organization.

 

 

About James Smith

James Smith is one of the best author of health care. His articles have appeared in a number of health care sites before and now he is writing on health care for us on regular basis.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

ăn dặm kiểu NhậtResponsive WordPress Themenhà cấp 4 nông thônthời trang trẻ emgiày cao gótshop giày nữdownload wordpress pluginsmẫu biệt thự đẹpepichouseáo sơ mi nữhouse beautiful